These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1682934)

  • 1. A 20 amino acid synthetic peptide of a region from the 55 kDa human TNF receptor inhibits cytolytic and binding activities of recombinant human tumour necrosis factor in vitro.
    Hwang CD; Gatanaga M; Innins EK; Yamamoto RS; Granger GA; Gatanaga T
    Proc Biol Sci; 1991 Aug; 245(1313):115-9. PubMed ID: 1682934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the binding site of 55kDa tumor necrosis factor receptor by synthetic peptides.
    Lie BL; Tunemoto D; Hemmi H; Mizukami Y; Fukuda H; Kikuchi H; Kato S; Numao N
    Biochem Biophys Res Commun; 1992 Oct; 188(2):503-9. PubMed ID: 1332702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of 55- and 75-kDa tumor necrosis factor membrane receptors in the regulation of intercellular adhesion molecules-1 expression by HL-60 human promyelocytic leukemia cells in vitro.
    Abe Y; Gatanaga M; Osuka Y; Kimura S; Burger RA; Granger GA; Gatanaga T
    J Immunol; 1993 Jun; 150(11):5070-9. PubMed ID: 8098725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes. TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma.
    Andrews JS; Berger AE; Ware CF
    J Immunol; 1990 Apr; 144(7):2582-91. PubMed ID: 1969453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human TNF mutants with selective activity on the p55 receptor.
    Van Ostade X; Vandenabeele P; Everaerdt B; Loetscher H; Gentz R; Brockhaus M; Lesslauer W; Tavernier J; Brouckaert P; Fiers W
    Nature; 1993 Jan; 361(6409):266-9. PubMed ID: 8380906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of tumor necrosis factor and lymphotoxin blocking factor(s) in the ascites of patients with advanced and recurrent ovarian cancer.
    Cappuccini F; Yamamoto RS; DiSaia PJ; Grosen EA; Gatanaga M; Lucci JA; Ininns EK; Gatanaga T; Granger GA
    Lymphokine Cytokine Res; 1991 Jun; 10(3):225-9. PubMed ID: 1653048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins.
    Scallon BJ; Trinh H; Nedelman M; Brennan FM; Feldmann M; Ghrayeb J
    Cytokine; 1995 Nov; 7(8):759-70. PubMed ID: 8664442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of receptor occupancy to the kinetics of cell death mediated by tumor necrosis factor.
    Coffman FD; Green LM; Ware CF
    Lymphokine Res; 1988; 7(4):371-83. PubMed ID: 2850412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients.
    Gatanaga T; Hwang CD; Kohr W; Cappuccini F; Lucci JA; Jeffes EW; Lentz R; Tomich J; Yamamoto RS; Granger GA
    Proc Natl Acad Sci U S A; 1990 Nov; 87(22):8781-4. PubMed ID: 2174164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor.
    Seckinger P; Zhang JH; Hauptmann B; Dayer JM
    Proc Natl Acad Sci U S A; 1990 Jul; 87(13):5188-92. PubMed ID: 2164226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor.
    Nophar Y; Kemper O; Brakebusch C; Englemann H; Zwang R; Aderka D; Holtmann H; Wallach D
    EMBO J; 1990 Oct; 9(10):3269-78. PubMed ID: 1698610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peptidomimetic antagonist of TNF-alpha-mediated cytotoxicity identified from a phage-displayed random peptide library.
    Chirinos-Rojas CL; Steward MW; Partidos CD
    J Immunol; 1998 Nov; 161(10):5621-6. PubMed ID: 9820541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ligand binding and antiproliferative effects of tumor necrosis factor and lymphotoxin by soluble forms of recombinant P60 and P80 receptors.
    Higuchi M; Aggarwal BB
    Biochem Biophys Res Commun; 1992 Jan; 182(2):638-43. PubMed ID: 1310388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
    Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
    Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity.
    Rathjen DA; Ferrante A; Aston R
    Immunology; 1993 Oct; 80(2):293-9. PubMed ID: 8262557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
    Qin W; Feng J; Li Y; Lin Z; Shen B
    Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor-alpha induced receptor aggregation.
    Pennica D; Kohr WJ; Fendly BM; Shire SJ; Raab HE; Borchardt PE; Lewis M; Goeddel DV
    Biochemistry; 1992 Feb; 31(4):1134-41. PubMed ID: 1310420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells.
    Loetscher H; Schlaeger EJ; Lahm HW; Pan YC; Lesslauer W; Brockhaus M
    J Biol Chem; 1990 Nov; 265(33):20131-8. PubMed ID: 2173696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor.
    Kohno T; Brewer MT; Baker SL; Schwartz PE; King MW; Hale KK; Squires CH; Thompson RC; Vannice JL
    Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8331-5. PubMed ID: 2172983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological activity of mutants of human tumour necrosis factor-alpha.
    Kircheis R; Milleck J; Korobko VG; Shingarova LN; Behnke D; Schmidt HE
    Immunology; 1992 Jul; 76(3):433-8. PubMed ID: 1526652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.